Photo of Robert W. Holloway, MD

Robert W. Holloway, MD

Medical Director (Gyn Onc), Gynecologic Oncologist

Research Area:

Expertise of Robert W. Holloway, MD

6 items. To interact with these items, press Control-Option-Shift-Right Arrow
Biography

Dr. Robert W. Holloway, MD is a board-certified gynecology oncologist in Orlando. Dr. Holloway joined the Florida Hospital Cancer Institute in 1994, and serves as the medical director of the Gynecologic Oncology Program. A graduate of Vanderbilt University School of Medicine, Dr. Holloway completed his OB/GYN residency at the University of Alabama at Birmingham and his fellowship in gynecologic oncology at Georgetown University in Washington, DC. Dr. Holloway is a Fellow of the American College of Surgeons. Additionally, Dr. Holloway is the principal investigator for several clinical trials and lectures regularly both nationally and internationally. His major research interests are robotic surgery and novel ovarian cancer therapies. Surgeons from around the world routinely attend his advanced training programs in robotic surgery.

Education

Vanderbilt University Medical Center

Residency

University of Alabama Birmingham

Fellowship

Georgetown University Hospital

Specialty

Gynecology Oncology

Board Certifications

American Board of Obstetrics & Gynecology

Publications of Robert W. Holloway, MD
  • Neoadjuvant chemotherapy with bevacizumab for locally advanced vulvar cancer
    , INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

  • Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer
    , CANCER

  • Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies
    , GYNECOLOGIC ONCOLOGY

    More sources loaded

  • Standardized Titration Protocol Reduces the Incidence of Paclitaxel Infusion-Related Hypersensitivity Reactions
    , JCO ONCOLOGY PRACTICE

  • Prognostic features of the tumor microenvironment in high-grade serous ovarian cancer and dietary immunomodulation
    , LIFE SCIENCES

  • Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)
    , GYNECOLOGIC ONCOLOGY

  • Efficacy and safety of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy
    , INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

  • Management of immune-related adverse events in patients with primary advanced or recurrent endometrial cancer: dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
    , INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

  • Patient-reported outcomes (PROs) in patients (pts) with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
    , ANNALS OF ONCOLOGY

  • Post-surgical ctDNA-based molecular residual disease detection in patients with stage I endometrial cancer
    , GYNECOLOGIC ONCOLOGY